TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30201679
Drug: Clinical decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical decision support (CDS) intervention implemented in family medicine clinics
Study: 30201679
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (general internal medicine clinics)
Study: 25403709
Drug: Individualised dietetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised dietetic advice and regular weekly follow-up (INT)
Study: 12219472
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antioxidants and zinc
Study: 12219472
Drug: Photodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic treatment of certain forms of CNV
Study: 12219472
Drug: Prophylactic laser
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic laser treatment of soft drusen maculopathy
Study: 9926184
Drug: Tramadol (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (3.0 mg.kg‐1)
Study: 9404175
Drug: Nalbuphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.3 mg.kg‐1)
Study: 9926184
Drug: Saline (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.2 ml.kg‐1)
Study: 9926184
Drug: Pethidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (1.5 mg.kg‐1)
Study: 7486039
Drug: Cisatracurium (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 60 s (Pilot Group A, n = 5)
Study: 7486039
Drug: Cisatracurium (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 30 s (Pilot Group B, n = 5)
Study: 7486039
Drug: Cisatracurium (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 5-10 s (Group C, n = 30)
Study: 7486039
Drug: Vecuronium (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.10 mg/kg, 2 x ED90) administered over 5-10 s (Group D, n = 30)
Study: 23494656
Drug: rhLAMAN (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhLAMAN (recombinant human alpha-mannosidase) administered weekly via intravenous enzyme replacement therapy (ERT) for 12 months
Study: 16424422
Drug: R-albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-albuterol
Study: 12814158
Drug: Budesonide/formoterol single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol single inhaler (Symbicort Turbuhaler) 160/4.5 microg delivered dose, two inhalations bid
Study: 1536399
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin solution
Study: 6379911
Drug: Tendamistate 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tendamistate 400 mg
Study: 31166390
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG), no surface treatment
Study: 29425211
Drug: Bioactive Food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioactive Food Compound (BFC) 40 g daily
Study: 24750471
Drug: Implant-supported partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported partial dentures (IRPDs)
Study: 24750471
Drug: Implant-fixed partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-fixed partial dentures (IFPDs)
Study: 18331607
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg bid)
Study: 20590747
Drug: Voglibose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.2 mg tid)
Study: 15763454
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of oral sustained-release theophylline
Study: 11884816
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol infusion (loading dose of 0.8 mg.kg(‐1) followed by continuous infusion of 30 microg.kg(‐1)min(‐1))
Study: 2355819
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg; nBB)
Study: 2355819
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg; sBB)
Study: 2355819
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg; nBB)
Study: 367086
Drug: i.v. verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. verapamil (0.15 mg/kg body weight)
Study: 367086
Drug: oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral verapamil (80 mg)
Study: 367086
Drug: oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral verapamil (240 mg)
Study: 367086
Drug: oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral verapamil (320 mg)
Study: 367086
Drug: oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral verapamil (400 mg)
Study: 367086
Drug: chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chronic oral therapy with progressively increasing doses of verapamil
Study: 26175087
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation (200 mg iron sucrose)
Study: 19139440
Drug: IFN‐alpha‐2b 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks (arm A)
Study: 19139440
Drug: IFN‐alpha‐2b 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha‐2b 15 x 10(6) U/m2 IV x 5/7 days weekly x 4 weeks followed by IFN‐alpha‐2b 10 x 10(6) U administered subcutaneously three times a week for 48 weeks (arm B)
Study: 9781830
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (50 mg)
Study: 9781830
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release dipyridamole (400 mg/day)
Study: 7830201
Drug: Stabilization splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization splint treatment (experimental group)
Study: 9090684
Drug: Oral dihydroergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dihydroergotamine (DHE)
Study: 27440869
Drug: Golimumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (any dose)
Study: 19171629
Drug: Psychostimulant medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychostimulant medications for ADHD
Study: 22854901
Drug: Carbamazepine up
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine up to 600 mg/day
Study: 12617742
Drug: 80 ml
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 ml contrast material injected before CT scan (group 1; n=7)
Study: 12617742
Drug: 80 ml
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 ml contrast material injected before CT scan (group 2; n=7)
Study: 2108884
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day leuprorelin given subcutaneously plus 250 mg flutamide three times a day
Study: 2108884
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day leuprorelin given subcutaneously
Study: 2108884
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of leuprorelin and flutamide
Study: 6446008
Drug: Terbutaline 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.50 mg by aerosol inhalation
Study: 6446008
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 0.04 mg by aerosol inhalation
Study: 31179798
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical treatment and physical therapy program)
Study: 31847717
Drug: 1-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month treatment with inhaled budesonide (200 μg, twice daily)
Study: 31847717
Drug: 2-month treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-month treatment with inhaled budesonide (200 μg, twice daily)
Study: 31847717
Drug: 4-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month treatment with inhaled budesonide (200 μg, twice daily)
Study: 25012275
Drug: Yoga practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga practice (1 hour daily for 3 months)
Study: 20483664
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH (150 IU daily for 7 days)
Study: 16271907
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone 2.5 mg/day
Study: 10451805
Drug: Metoclopramide (MCP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (MCP), 5 mg every 8 hours for 2 months
Study: 10451805
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered every 8 hours for 2 months
Study: 7598054
Drug: High-resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-resistant starch diet (39.0 +/- 3.0 g/d)
Study: 7598054
Drug: Low-resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-resistant starch diet (5.0 +/- 0.4 g/d)
Study: 115562
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (50 ml/kg of amino acid solution with 10 or 25 g/dl glucose plus 500 ml of soybean emulsion for 24 hours before and 5 days after operation)
Study: 31353177
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine 0.1 mg (group M+)
Study: 31353177
Drug: Posterior quadratus
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior quadratus lumborum block using 0.3% ropivacaine (0.45 mL/kg each side, maximum 150 mg) (group pQ+)
Study: 26323451
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and Root Planing (SRP) with adjunctive Tetracycline Fibers
Study: 26323451
Drug: Both SRP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SRP and SRP with adjunctive Tetracycline Fibers
Study: 22091563
Drug: Once‐yearly intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐yearly intravenous (IV) ZOL 5 mg
Study: 19331488
Drug: 0.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 g/kg alcohol (placebo)
Study: 12950437
Drug: Reversible inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversible inhibitors of monoamine oxidase type A (RIMAs)
Study: 12950437
Drug: SSRIs (fluvoxamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (fluvoxamine, paroxetine, sertraline)
Study: 12950437
Drug: Gabergic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabergic drugs (clonazepam, gabapentin, pregabalin)
Study: 12950437
Drug: Buspirone, tricyclics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone, tricyclics, beta-blockers
Study: 12950437
Drug: Paroxetine, clonazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine, clonazepam, sertraline, brofaromine
Study: 9132323
Drug: Aceclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac (100 mg bid)
Study: 1862787
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 0.12 mg/kg
Study: 1862787
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 0.20 mg/kg
Study: 30869183
Drug: Insulin degludec/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/insulin aspart (IDegAsp) twice daily
Study: 30869183
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (BIAsp 30) twice daily
Study: 15285979
Drug: Low-dose cortisol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cortisol (10 mg/day) for 1 month
Study: 9502664
Drug: Misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (50 mcg every 4 hours until delivery)
Study: 9502664
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (0.5 mg) followed by intravenous oxytocin infusion (Control)
Study: 2898457
Drug: BRL 26830A
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 26830A 50 mg qid
Study: 11595776
Drug: Orlistat therapy
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat therapy
Study: 29659879
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (off orlistat)
Study: 26571891
Drug: Plum blossom
Normalized name: OCTISALATE 4.7 g in 100 g / ZINC OXIDE 15 g in 100 g TOPICAL LIPSTICK [TATCHA THE KISSU LIP TINT SPF 25 PLUM BLOSSOM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plum blossom needle tapping therapy at key points combined with Bobath therapy
Study: 26571891
Drug: Bobath manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath manipulation therapy
Study: 24260334
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions, 5 days/week, 60 minutes each, 100% oxygen at 1.5 ATA
Study: 21148720
Drug: rSP-C surfactant
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: rSP-C surfactant (up to eight doses administered over 96 hours)
Study: 9951781
Drug: Clodronate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 100 mg i.m. every week
Study: 9951781
Drug: Clodronate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 100 mg i.m. every two weeks
Study: 8537627
Drug: Silver-impregnated cuff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-impregnated cuff (Ag-CC)
Study: 1968858
Drug: Scoring system
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scoring system for calculating the dose of vaginal prostaglandin E2 tablets
Study: 1968858
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of 3 mg vaginal prostaglandin E2 tablets
Study: 29947083
Drug: Burosumab 1
Normalized name: Burosumab 10 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burosumab 1 mg/kg subcutaneously every 4 weeks (n = 68)
Study: 27357971
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celecoxib (loading dose the night before surgery then twice daily for 10 days)
Study: 20814217
Drug: Platelet gel
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet gel (PG) applied locally
Study: 17413292
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone infusion (2.3 microg/kg/h)
Study: 12151889
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Hohmann operation)
Study: 2107518
Drug: Haemophilus b
Normalized name: HAEMOPHILUS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus b conjugate vaccine (meningococcal protein conjugate), PedvaxHIB (PRP‐OMPC)
Study: 373391
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dosage of clomipramine (150 mg at night for 10 days)
Study: 373391
Drug: Divided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided daily dosage of clomipramine (150 mg three times daily for 10 days)
Study: 373391
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dosage of clomipramine
Study: 373391
Drug: Divided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided daily dosage of clomipramine
Study: 30832230
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of Glutamine (Gln) for 14 days
Study: 30899946
Drug: SRP followed
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP followed by topical use of rhubarb extract
Study: 16275936
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) with autologous stem-cell transplantation (melphalan 200 mg/m2 IV or melphalan 140 mg/m2 IV plus busulfan 16 mg/kg orally)
Study: 16275936
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (CCT; monthly courses of vincristine, melphalan, cyclophosphamide, and prednisone)
Study: 12561063
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of Tc‐99m tin colloid (0.4‐5 microm)
Study: 12561063
Drug: Subdermal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal injection of radiocolloids
Study: 2268864
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 to 40 mg daily for six months)
Study: 6104614
Drug: Nadolol (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (once daily for 12 weeks)
Study: 31734589
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative body radiotherapy (SABR) at a dose of 20Gy in 1 fraction to each metastasis
Study: 30192018
Drug: Ecopipam (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam (50 mg/day for weight <34 kg, 100 mg/day for weight >34 kg)
Study: 27434094
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone alone (90 mg once daily)
Study: 27434094
Drug: Estradiol addition
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol addition (2 mg twice daily)
Study: 25112096
Drug: Electric-thermal Bian-stone
Normalized name: ditch stonecroft extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric-thermal Bian-stone therapy (group A)
Study: 25112096
Drug: Moxibustion box
Normalized name: ALLERGENIC EXTRACT, BOX ELDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion box therapy (group B)
Study: 22804796
Drug: 12-week exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week exercise programme including pelvic floor muscle training (PFMT), conducted between 20 and 36 weeks of gestation, with one weekly group session led by physiotherapists and home exercises encouraged at least twice a week.
Study: 19464164
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) in triple-negative tumours
Study: 19464164
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) in HER2-positive tumours
Study: 17594986
Drug: I'm-Yunity (Coriolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: I'm-Yunity (Coriolus versicolor) 1200 mg, three times daily for 14 days
Study: 15446758
Drug: NK-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK-1 receptor antagonists (specific drug not mentioned), administered before chemotherapy and continued twice daily for five days.
Study: 15446758
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with granisetron and dexamethasone.
Study: 15446758
Drug: NK-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK-1 receptor antagonists (specific drug not mentioned), cost of Can$6.60 per dose.
Study: 15446758
Drug: NK-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK-1 receptor antagonists (specific drug not mentioned), total cost for five days of therapy.
Study: 29273485
Drug: Omnitrope (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnitrope (0.08 or 0.16mg GH/kg/wk divided into 7 equal daily doses)
Study: 18827177
Drug: 10 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg/kg bevacizumab (Avastin) administered every 2 weeks
Study: 15940776
Drug: ATP 90
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP 90 mg once daily
Study: 8317411
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg (three premeal doses)
Study: 8317411
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (single morning dose)
Study: 28806907
Drug: Estazolam (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (1-2 mg/day taken 30 minutes before sleep for 4 weeks)
Study: 21672316
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml 6% hydroxyethyl starch 130/0.4 (HES)
Study: 21672316
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml 4% succinylated gelatine (GEL)
Study: 16513858
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (40 mg)
Study: 16513858
Drug: Osmotic-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic-release methylphenidate (90 mg)
Study: 12753943
Drug: CEE+MPA (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE+MPA (0.625 mg conjugated equine estrogens combined with 2.5 mg medroxyprogesterone acetate)
Study: 6963097
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administration during maintenance therapy with digoxin